KemPharm Company Profile (NASDAQ:KMPH)

About KemPharm

KemPharm logoKemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company's product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP). The Company is developing KP201/APAP as an immediate release (IR), a product candidate for the short-term, or no longer than 14 days for the management of acute pain. The Company has designed KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. The Company also focuses on developing the pipeline of additional prodrug product candidates that targets pain and attention deficit hyperactivity disorder (ADHD). The Company's products include KP201/IR (APAP-free), KP511/ER, KP415, KP606/IR and KP746.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: KMPH
  • CUSIP:
Key Metrics:
  • Previous Close: $3.85
  • 50 Day Moving Average: $3.55
  • 200 Day Moving Average: $3.98
  • 52-Week Range: $2.90 - $19.75
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.45
  • P/E Growth: 0.00
  • Market Cap: $57.85M
  • Outstanding Shares: 14,646,000
  • Beta: -1.46
Profitability:
  • Return on Assets: -17.21%
Debt:
  • Debt-to-Equity Ratio: -9.26%
  • Current Ratio: 11.45%
  • Quick Ratio: 11.45%
Additional Links:
Companies Related to KemPharm:

Analyst Ratings

Consensus Ratings for KemPharm (NASDAQ:KMPH) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.00 (203.80% upside)

Analysts' Ratings History for KemPharm (NASDAQ:KMPH)
Show:
DateFirmActionRatingPrice TargetDetails
12/20/2016Canaccord GenuityInitiated CoverageBuy$9.00View Rating Details
12/14/2016Oppenheimer Holdings, Inc.Set Price TargetBuy$13.00View Rating Details
5/8/2016Royal Bank of CanadaReiterated RatingBuyView Rating Details
8/15/2015Cowen and CompanyReiterated RatingBuyView Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for KemPharm (NASDAQ:KMPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2017        
8/10/2016Q2($0.94)($0.58)ViewListenView Earnings Details
5/12/2016Q1($0.46)($0.20)ViewListenView Earnings Details
3/10/2016Q4($0.50)($0.64)ViewListenView Earnings Details
11/12/2015Q315($0.42)($0.68)ViewListenView Earnings Details
8/13/2015Q215($0.47)($2.45)ViewListenView Earnings Details
5/27/2015Q1($0.49)($2.50)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for KemPharm (NASDAQ:KMPH)
Current Year EPS Consensus Estimate: $-1.77 EPS
Next Year EPS Consensus Estimate: $-2.72 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.56)($0.56)($0.56)
Q2 20161($0.59)($0.59)($0.59)
Q3 20161($0.70)($0.70)($0.70)
Q4 20161($0.73)($0.73)($0.73)
Q1 20171($0.69)($0.69)($0.69)
Q2 20171($0.69)($0.69)($0.69)
Q3 20171($0.69)($0.69)($0.69)
Q4 20171($0.80)($0.80)($0.80)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for KemPharm (NASDAQ:KMPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for KemPharm (NASDAQ:KMPH)
Insider Ownership Percentage: 22.80%
Institutional Ownership Percentage: 44.36%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/30/2016Daniel L CohenEVPBuy5,000$3.50$17,500.00View SEC Filing  
9/6/2016Daniel L CohenEVPBuy10,000$4.75$47,500.00View SEC Filing  
8/17/2016Travis C MickleCEOBuy5,000$4.95$24,750.00View SEC Filing  
3/29/2016Travis C MickleCEOBuy2,450$14.57$35,696.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for KemPharm (NASDAQ:KMPH)
DateHeadline
News IconInvestor Focus: Watching Shares of KemPharm, Inc. (NASDAQ:KMPH) - SKV News (NASDAQ:KMPH)
skvnews.com - February 25 at 12:27 AM
4-traders.com logoKemPharm : Announces Additional Patent Protection for Prodrug Portfolio (NASDAQ:KMPH)
www.4-traders.com - February 24 at 7:26 PM
News IconAre Analysts Optimistic About Where KemPharm Inc (NASDAQ:KMPH) is Heading? - Winfield Review (NASDAQ:KMPH)
winfieldreview.com - February 24 at 9:59 AM
finance.yahoo.com logo7:31 am KemPharm announces issuance of two new patents by the USPTO, one related to the KP511 family of compounds and another related to KP201 (NASDAQ:KMPH)
finance.yahoo.com - February 23 at 6:09 PM
News IconShares Worth Watching: KemPharm Inc (NASDAQ:KMPH) - Rockville Register (NASDAQ:KMPH)
rockvilleregister.com - February 23 at 1:03 AM
News IconStock Update on Earnings & Estimates for KemPharm Inc (NASDAQ:KMPH) - Aiken Advocate (NASDAQ:KMPH)
aikenadvocate.com - February 23 at 1:03 AM
News IconKemPharm Inc KMPH Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:KMPH)
www.bioportfolio.com - February 18 at 9:58 AM
News IconAre Analysts Forecasting a Near-Term Upswing For KemPharm Inc (NASDAQ:KMPH)? - Winfield Review (NASDAQ:KMPH)
winfieldreview.com - February 17 at 1:13 PM
News IconLooking Ahead for KemPharm Inc (NASDAQ:KMPH); Are These Shares Ready to Go Higher? - Aiken Advocate (NASDAQ:KMPH)
aikenadvocate.com - February 17 at 1:13 PM
biz.yahoo.com logoKEMPHARM, INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:KMPH)
biz.yahoo.com - February 16 at 5:50 PM
News IconShares Making an Appearance on Today's Most Volatile List: KemPharm, Inc. (NASDAQ:KMPH) - Aiken Advocate (NASDAQ:KMPH)
aikenadvocate.com - February 13 at 7:14 PM
News IconAnalysts Ratings Update on Kamada Ltd. (NASDAQ:KMDA) KemPharm, Inc. (NASDAQ:KMPH) - Rives Journal (NASDAQ:KMPH)
rivesjournal.com - February 13 at 7:14 PM
openpr.com logoKemPharm Inc (NASDAQ:KMPH) Investor Lawsuit alleges False and Misleading Statements (NASDAQ:KMPH)
www.openpr.com - February 9 at 7:10 PM
finance.yahoo.com logoKemPharm to Present at Upcoming Investor Conferences (NASDAQ:KMPH)
finance.yahoo.com - February 7 at 7:27 PM
businesswire.com logoSHAREHOLDER ALERT: Goldberg Law PC Announces an ... - Business Wire (press release) (NASDAQ:KMPH)
www.businesswire.com - February 4 at 4:53 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of KemPharm, Inc. and Advises Investors with Losses to Contact the Firm (NASDAQ:KMPH)
finance.yahoo.com - February 3 at 11:52 PM
News IconInvesting Focus: Indicators in View on Shares of Kempharm Inc (KMPH) - Sherwood Daily (NASDAQ:KMPH)
sherwooddaily.com - February 3 at 4:58 AM
News IconTrading Scope: ADX and CCI Review for Kempharm Inc (KMPH) - Sherwood Daily (NASDAQ:KMPH)
sherwooddaily.com - February 1 at 6:58 PM
News IconNASDAQ:KMPH Investor News: Lawsuit alleges Misleading Statements by KemPharm Inc - GroundReport (NASDAQ:KMPH)
www.groundreport.com - February 1 at 6:58 PM
News IconCalibrating the Trade: Watching Technicals on Shares of Kempharm Inc (KMPH) - Sherwood Daily (NASDAQ:KMPH)
sherwooddaily.com - January 30 at 11:54 PM
businesswire.com logoCRITICAL INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of KemPharm, Inc. and Encourages ... - Business Wire (press release) (NASDAQ:KMPH)
www.businesswire.com - January 27 at 8:19 PM
News IconEarnings in Full Force, Analysts Take Aim at KemPharm Inc (NASDAQ:KMPH) - Wall Street Beacon (NASDAQ:KMPH)
wsbeacon.com - January 27 at 8:19 PM
finance.yahoo.com logoCRITICAL INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of KemPharm, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:KMPH)
finance.yahoo.com - January 27 at 8:19 PM
News IconAnalyst Consensus Estimates & Projections are in For Shares of KemPharm Inc (NASDAQ:KMPH) - Aiken Advocate (NASDAQ:KMPH)
aikenadvocate.com - January 26 at 5:37 AM
News IconTrading Indicator Check on Kempharm Inc (KMPH) - Sherwood Daily (NASDAQ:KMPH)
sherwooddaily.com - January 26 at 5:37 AM
4-traders.com logoKemPharm : U.S. Patents Awarded to Inventors in Iowa (Jan. 25) (NASDAQ:KMPH)
www.4-traders.com - January 25 at 7:34 PM
News IconKemPharm Inc KMPH Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:KMPH)
www.bioportfolio.com - January 25 at 7:34 PM
4-traders.com logoPomerantz Law Firm Investigates Claims On Behalf of Investors of KemPharm, Inc. - KMPH (NASDAQ:KMPH)
www.4-traders.com - January 23 at 11:30 PM
News IconInvestor Sphere: Keeping an Eye on Levels for Kempharm Inc (KMPH) - Sherwood Daily (NASDAQ:KMPH)
sherwooddaily.com - January 23 at 6:29 PM
prnewswire.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims ... - PR Newswire (press release) (NASDAQ:KMPH)
www.prnewswire.com - January 23 at 6:29 PM
prnewswire.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC ... - PR Newswire (press release) (NASDAQ:KMPH)
www.prnewswire.com - January 23 at 6:29 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of KemPharm, Inc. (KMPH) (NASDAQ:KMPH)
finance.yahoo.com - January 23 at 6:29 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of KemPharm, Inc. - KMPH (NASDAQ:KMPH)
finance.yahoo.com - January 23 at 6:29 PM
finance.yahoo.com logoShareholder Alert: Lundin Law PC Announces an Investigation of KemPharm, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:KMPH)
finance.yahoo.com - January 23 at 6:29 PM
prnewswire.com logoKEMPHARM NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Significant Losses Investing In ... - PR Newswire (press release) (NASDAQ:KMPH)
www.prnewswire.com - January 21 at 5:58 PM
finance.yahoo.com logoKEMPHARM NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Significant Losses Investing In KemPharm, Inc. To Contact The Firm (NASDAQ:KMPH)
finance.yahoo.com - January 21 at 2:27 AM
4-traders.com logoDAVIDSTEA INC. : Change in Directors or Principal Officers, Other Events (form 8-K) (NASDAQ:KMPH)
www.4-traders.com - January 20 at 4:25 PM
finance.yahoo.com logoRobbins Arroyo LLP: KemPharm, Inc. (KMPH) Misled Shareholders According to a Recently Filed Class Action (NASDAQ:KMPH)
finance.yahoo.com - January 20 at 4:25 PM
News IconGearing Up For a Bull Run? Analysts Weigh in on KemPharm Inc (NASDAQ:KMPH) - Wall Street Beacon (NASDAQ:KMPH)
wsbeacon.com - January 19 at 7:58 PM
News IconWatching the Charts on Shares of Kempharm Inc (KMPH) - Sherwood Daily (NASDAQ:KMPH)
sherwooddaily.com - January 18 at 4:36 AM
News IconShares Skittish Ahead of The Bell: KemPharm, Inc. (NASDAQ:KMPH) - Wall Street Beacon (NASDAQ:KMPH)
wsbeacon.com - January 13 at 7:26 PM
finance.yahoo.com logoKemPharm CEO On Recent Results, Catalysts And Prospects ... - Yahoo Finance (NASDAQ:KMPH)
finance.yahoo.com - January 12 at 11:41 PM
News IconWill The Needle Move For KemPharm Inc (NASDAQ:KMPH) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:KMPH)
wsbeacon.com - January 12 at 11:41 PM
us.rd.yahoo.com logoKemPharm Reports Positive Data from Phase 1 Intranasal Pharmacokinetic Study of KP511, An Investigational Prodrug of Hydromorphone for the Treatment of Pain (NASDAQ:KMPH)
us.rd.yahoo.com - January 9 at 11:58 PM
streetinsider.com logoForm 8-K KEMPHARM, INC For: Jan 09 - StreetInsider.com (NASDAQ:KMPH)
www.streetinsider.com - January 9 at 6:56 PM
globenewswire.com logoKemPharm to Present at Biotech Showcase 2017 - GlobeNewswire (press release) (NASDAQ:KMPH)
globenewswire.com - January 5 at 7:28 PM
publicnow.com logoKemPharm to Present at Biotech Showcase 2017 (NASDAQ:KMPH)
www.publicnow.com - January 4 at 7:00 PM
stocksdaily.net logoKemPharm Inc (NASDAQ:KMPH) EPS Projection At $-0.73? - Stocks Daily (NASDAQ:KMPH)
www.stocksdaily.net - December 31 at 11:03 PM
fxpips.com logoThese Stocks are Gapping Up Before the Bell – AAPC, OCC, KMPH, ABIO, GLMD, HIL, AKBA (NASDAQ:KMPH)
www.fxpips.com - December 21 at 7:00 PM
4-traders.com logoKemPharm : Granted "Fast Track" Designation for KP201/IR (NASDAQ:KMPH)
www.4-traders.com - December 21 at 7:00 PM

Social

What is KemPharm's stock symbol?

KemPharm trades on the NASDAQ under the ticker symbol "KMPH."

Where is KemPharm's stock going? Where will KemPharm's stock price be in 2017?

3 brokerages have issued 1-year price targets for KemPharm's stock. Their predictions range from $9.00 to $14.00. On average, they expect KemPharm's share price to reach $12.00 in the next twelve months.

When will KemPharm announce their earnings?

KemPharm is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.

Who owns KemPharm stock?

KemPharm's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include DSC Advisors L.P. (9.96%), Deerfield Management Co. (7.40%), Alyeska Investment Group L.P. (6.82%), Federated Investors Inc. PA (1.37%) and Menta Capital LLC (0.32%). Company insiders that own KemPharm stock include Daniel L Cohen and Travis C Mickle.

Who bought KemPharm stock? Who is buying KemPharm stock?

KemPharm's stock was acquired by a variety of institutional investors in the last quarter, including DSC Advisors L.P. and Alyeska Investment Group L.P.. Company insiders that have bought KemPharm stock in the last two years include Daniel L Cohen and Travis C Mickle.

How do I buy KemPharm stock?

Shares of KemPharm can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of KemPharm stock cost?

One share of KemPharm stock can currently be purchased for approximately $3.95.

KemPharm (NASDAQ:KMPH) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for KemPharm (NASDAQ:KMPH)

Earnings History Chart

Earnings by Quarter for KemPharm (NASDAQ:KMPH)

Dividend History Chart

Dividend Payments by Quarter for KemPharm (NASDAQ:KMPH)

Last Updated on 2/25/2017 by MarketBeat.com Staff